Or­biMed lines up $551M gam­ble on Chi­na, In­dia biotech sec­tors

You want more ev­i­dence of Asia’s boom­ing biotech sec­tor? Or­biMed can pro­vide it.

The VC an­nounced this morn­ing that its third Asia-fo­cused pri­vate eq­ui­ty fund raised a whop­ping $551 mil­lion, far sur­pass­ing the $325 mil­lion gath­ered the last time around.

“This new, larg­er fund re­flects our en­thu­si­asm for the in­vest­ment op­por­tu­ni­ties in Chi­na and In­dia, which have health­care mar­ket growth rates far su­pe­ri­or to most de­vel­oped coun­tries,” not­ed Carter Neild, an Or­biMed Gen­er­al Part­ner.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER